Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Managing Weight in NAFLD/NASH

Source: Hot Topics in NASH: Current Controversies and New Developments in Fatty Liver Disease
What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.
Rotonya Carr, MD
Released: July 8, 2020

What should our patients with NAFLD eat? Listen as expert hepatologist Rotonya Carr, MD, explores the evidence behind different diets in NAFLD/NASH.

Download the slides from this podcast at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics/weight-management-in-nafld-nash/slideset

See more NASH topics at: https://www.clinicaloptions.com/internal-medicine/programs/2019-nash-hot-topics

Acknowledgements

Provided by the American Gastroenterology Association.
Contact Info

American Gastroenterological Association (AGA)
4930 Del Ray Avenue
Bethesda, MD 20814
Phone: (301) 654-2055
Fax: (301) 654-5920
Email: member@gastro.org

Produced in collaboration with
Endocrine Society Logo
Supported by educational grants from
Allergan
Gilead Sciences
Intercept Pharmaceuticals, Inc.

Information on this Educational Activity

Faculty

Rotonya Carr, MD

Assistant Professor of Medicine
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania

Rotonya Carr, MD, has disclosed that she has received funds for research support from Intercept and consulting fees from Boehringer.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.

Program Medium

This program has been made available online.

Related Content

Hear Stephen A. Harrison, MD, COL (Ret.), FAASLD, weigh the latest perspectives on wet biomarkers, imaging, and combination tests for NASH from CCO

Stephen A. Harrison, MD, COL (Ret.), FAASLD Released: July 7, 2020

Hear CCO faculty Philip Newsome discuss the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Philip N. Newsome, PhD, FRCPE Released: February 12, 2020

CCO faculty Dr Juan Frias discusses the agents in late-phase clinical trials and their potential use in treatment of NASH and fibrosis

Juan Pablo Frias, MD, FACE Released: February 5, 2020

Juan Frias and Philip Newsome: Learn about the agents in phase II and III clinical trials and their potential use in treatment.

Juan Pablo Frias, MD, FACE Philip N. Newsome, PhD, FRCPE Released: January 28, 2020

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue